Presentations are solicited for polymorphism of substances related to the development of active pharmaceutical ingredients. This includes methods for discovering and producing the most stable form. The impact of form selection on a reproducible manufacturing process for a stable drug substance or formulated drug product is also of interest. Papers which examine strategies/methodologies for the control of polymorphism during crystallization, drying, storage and formulation are most welcomed. This may include but is not limited to the affect of solvent composition, particle size, shear environment, seeding and reactor configuration. The novel use of process analytical technologies for monitoring and control of crystallizations is also an important component to be covered in this session.

Crystallization and Evaporation

Pharmaceuticals (15b)